Orthopedic innovation rarely originates inside the companies that ultimately scale it. Over the past 15 years, the industry has increasingly relied on startups to discover new technologies, validate surgeon adoption and create the innovations that large companies later integrate and commercialize. Understanding how that system works is essential for everyone operating within it.

Orthopedics is often described as a mature sector. It is dominated by global incumbents, characterized by high switching costs in the operating room and supported by deeply embedded commercial infrastructure. Yet many of the industry’s most meaningful step changes in technology, workflow and care delivery originate outside those organizations.

Startups are not peripheral to orthopedics. They are a structural mechanism through which the category renews itself, pipelines innovation and adapts to shifts in capital markets, care models and manufacturing capacity.

Why the Ecosystem Is Shifting

From 2010 to 2025, industry databases captured more than 200 orthopedic M&A deals with roughly $96 billion in total declared deal value across approximately 75 disclosed transactions — spanning joint reconstruction, spine, trauma, sports medicine, orthobiologics and digital surgery.

The deal structures themselves tell the story. Long-term partnerships, staged investment, build-to-buy agreements, licensing arrangements, earn-out structures and distribution collaborations have all become standard. These formats signal a clear preference among strategics to validate adoption before committing full capital and favor the benefits that startups offer.

Strategic Portfolio Reshaping. In late 2025, Johnson & Johnson announced its intention to separate DePuy Synthes into a standalone entity — with subsequent reporting suggesting a potential sale exceeding $20 billion. This reflects a broader strategic realignment across healthcare: large conglomerates reassessing portfolio focus and capital allocation, favoring tighter alignment over broad internal expansion.

Private Equity’s Expanding Footprint. Private equity (PE) capital is now active across the entire orthopedic value chain. More than 16 PE-backed management platforms are actively consolidating orthopedic practices, while PE investors aggregate manufacturing capabilities, particularly in spine, additive manufacturing and specialized supply chains.

For startups, this consolidation has had a significant practical effect by lowering barriers to access ISO-compliant production without heavy upfront capital expenditure. CDMOs now provide scalable quality systems and integrated capabilities that would previously have required years of internal investment to build.

Internal Capital Prioritizes Enabling Technologies. A parallel shift is visible in the way that established orthopedic companies allocate their R&D budgets. Much of the recent internal investment across the sector has moved toward enabling technologies: robotics, navigation, digital surgery platforms and software infrastructure. These technologies support surgical workflows and can scale across multiple implant systems.

As a result, step-change implant innovation increasingly emerges from startups rather than internal programs. Large companies continue to advance incremental improvements within existing portfolios, but more disruptive technologies frequently originate outside the organization.

Behavior Matters More Than Technology

When a new orthopedic technology launches, the question that determines its future is rarely technical performance alone. The more important question concerns user behavior, adoption dynamics and distribution integration. Does the technology become part of the surgeon’s routine? Is adoption contagious and sustained? Can it integrate into existing supply chains, sales systems and platforms?

Product market fit in orthopedics is not a feature checklist. It is behavioral proof. A product has true market fit when surgeons choose it repeatedly, operating teams become faster with it over time, and adoption spreads peer to peer rather than purely through top-down promotion.

These signals matter because orthopedic surgery is a highly procedural discipline. Technologies succeed when they become embedded in daily clinical workflow, not simply when they outperform a predicate in a controlled study.

Startups have structural advantages in discovering behavioral fit that larger organizations often cannot replicate:

• They start with a single workflow. Incumbents often start from portfolio fit. Startups can begin from a single moment in the operating room that feels broken and build backward from that point.
• They co-design with early adopters in real time. In orthopedics, adoption is heavily surgeon-led. Startups can embed with early users and iterate instrumentation, packaging, training and workflow until the production adoption feels inevitable.
• They optimize for time, not just outcomes. Surgeons and their teams feel time pressure every day. Startups can win by reliably reducing surgical steps, tray complexity, cognitive load and variability.
• They obsess over the denominator. The difference between a product that works in one key opinion leader’s hands and one that works across diverse surgeons is usually not based on the implant or algorithm; it is based on reproducibility, usability and error tolerance.

The most effective startups structure their early clinical work around capital-efficient validation pathways to generate meaningful behavioral proof without excessive burn and sequencing evidence in a way that compounds commercial leverage over time.

• Designing for Reproducibility. Startups can design for usability, error tolerance and procedural consistency early in development because they are not constrained by legacy platforms or existing instrumentation systems. This matters enormously for adoption at scale.

Reproducibility, which depends on education, training, manufacturing controls and breadth of design input, can mean the difference between a product that works in a single surgeon’s hands and one that works reliably across hundreds of surgeons.

When these factors align, product market fit becomes visible through surgeon behavior. At that point, the innovation often becomes strategically interesting to the larger orthopedic companies that have the commercial infrastructure to scale it.

Changing Landscape

A new equilibrium is forming across the orthopedic industry. Strategics seek optionality and proof before full integration. Financial sponsors provide scale infrastructure across services and supply chains. And startups compress early risk through focused iteration, disciplined capital deployment and close surgeon collaboration.

Together, they form the front end of orthopedics’ innovation pipeline. Understanding the dynamics between them is increasingly essential for anyone building, funding or buying within the sector.

Editor’s Note: The next installment of this two-part series examines how startups and strategics work together in practice — and why acquisition so often beats internal development.

Maxwell Munford, Ph.D., is Founder and CEO of OSSTEC, a medtech company developing next-generation orthopedic implants built on deep technical expertise from Imperial College London. Secure your spot at OMTEC 2026 to hear Munford speak about turning supplier relationships into strategic partnerships.

Dan Pryor is an experienced industrial and medical technology executive and board director. He previously served as Executive Vice President at Enovis, where he helped lead its transformation into a global medical technology platform through more than 50 acquisitions and divestitures representing over $14 billion in enterprise value.

Save Supplier